Glaxosmithkline Intellectual Property Development Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11755311.5Aexternal-prioritypatent/EP2614058B1/en
Application filed by Glaxosmithkline Intellectual Property Development LimitedfiledCriticalGlaxosmithkline Intellectual Property Development Limited
Publication of CY1116709T1publicationCriticalpatent/CY1116709T1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Η παρούσα εφεύρεση κατευθύνεται σε νέα πολύμορφα και άλατα μιας ένωσης η οποία είναι αναστολέας δραστικότητας κινάσης.The present invention is directed to novel polymorphs and salts of a compound which is a kinase activity inhibitor.
POLYMORPHS AND SALTS OF N-[5-[4-(5-{[(2R,6S)-2,6-DIMETHYL-4-MORPHOLINYL]METHYL}-& xA;1,3-OXAZOL-2-YL)-1H-INDAZOL-6-YL]-2-(METHYLOXY)-3-PYRIDINYL]METHANESULFONAMIDE
POLYMORPHIC FORMS AND SALTS 6- (1H-INDOL-4-YL) -4- (5 - {[4- (1-METHYLETHYL) -1-PIPERAZINYL] METHYL} -1,3-OXAZOL-1-Y -INDAZOLIE AS RI3K INHIBITORS FOR USE IN THERAPY BC RESPIRATORY DISORDERS
Compounds derived from substituted nitrogen heterocyclics, ip receptor agonists; pharmaceutical composition; pharmaceutical combination; and use for the treatment of pulmonary arterial hypertension.
Compounds derived from 2- (ethynyl-pyridin-2-yl) -pyrazolidin-3-one, 2- (ethynyl-pyrimidin-2-yl) -pyrazolidin-3-one or 2- (ethynyl-pyridazin-3-yl) -pyrazzolidin-3-one; mglur5 positive allosteric modulators; preparation procedure; pharmaceutical composition; and its use to treat schizophrenia or cognitive diseases.